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Abstract: Currently, many sensitive molecules have been studied for effective oral administration.
These substances are biologically active compounds that mainly suffer early degradation in the
gastrointestinal tract (GIT) and physicochemical instability, inactivation and poor solubility and
permeability. The sensibility of the biomolecules has limited their oral administration in the body
and today is an important research topic to achieve desired effects in medicine field. Under this
perspective, various enhancement approaches have been studied as alternatives to increase their oral
bioavailability. Some of these strategies include functionalized polymers to provide specific useful
benefits as protection to the intestinal tract by preventing its degradation by stomach enzymes, to
increase their absorption, permeability, stability, and to make a proper release in the GIT. Due to
specific chemical groups, shapes and sizes, morphologies, mechanical properties, and degradation,
recent advances in functionalized polymers have opened the door to great possibilities to improve
the physicochemical characteristics of these biopharmaceuticals. Today, many biomolecules are
found in basic studies, preclinical steps, and others are late stage clinical development. This review
summarizes the contribution of functionalized polymers to enhance oral bioavailability of sensitive
molecules and their application status in medicine for different diseases. Future trends of these
polymers and their possible uses to achieve different formulation goals for oral delivery are also
covered in this manuscript.
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1. Introduction
A large number of proteins and peptides (vaccines, enzymes, hormones, cytokines, antibodies
nucleic acids and globulins) have found possible applications as biopharmaceuticals because they
can be used for the treatment of many diseases, such as diabetes (insulin), and malignant disorders,
including cancer. As a result of their importance in the medical field, today many biopharmaceuticals
make up about one-third of drugs currently in development [1]. However, they are sensitive molecules
that are hardly administered in their oral form, because of their several unfavorable physicochemical
properties, including large molecular size, susceptibility to enzymatic degradation, short plasma
half-life, ion permeability, immunogenicity, and the tendency to undergo aggregation, adsorption,
and denaturation [2]. The fast degradation of active substances in the gastrointestinal tract (GIT)
and poor permeability across the intestinal epithelium should be improved to achieve appropriate
concentrations in blood and to extend the residence time in the body; since to exert their health
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benefits, the active substances have to be delivered in the site of absorption. These factors, including
stability and circulation time in the gastrointestinal tract, strongly affect the effective absorption of
oral-delivered drugs, as well as the inability to reach their targets in an active form in vivo [3].
With the aim of reducing these constraints, some biopharmaceuticals are currently administrated
by intravenous, intramuscular or subcutaneous route, although their effects are generally poor, since
molecules cannot get to the active site in denatured way, or they are not allowed to cross the intestinal
barrier. This problem severely restricts the therapeutic value of the drugs, particularly for diabetes, the
case is more evident: less than 0.1% of the oral dose of insulin reaches the bloodstream intact [4]; thus,
due to their excessive degradation, it must be administered through injections and in repeated doses
to ensure their effect, which leads to poor patient compliance [5].
Other alternative routes to transport sensitive molecules include the buccal, intranasal, pulmonary,
transdermal, ocular, vaginal and rectal routes. In particular, oral transmucosal buccal delivery and
sublingual delivery have progressed far beyond the use of traditional dosage forms with novel
approaches, which could be engineered to deliver complex biomolecules. Details on these routes are
found in [6–8]; however, these alternatives have only had success in some cases, since both, the stability
of the formulations and their preparation are the most important hurdles for their oral delivery.
Consequently, several studies have focused on the research of suitable administration of these
molecules, but certainly, the increment in their oral bioavailability, adequate releasing in GIT and their
half-lives, in vivo, are one of the great challenges in the field of medicine [9].
In general, successful oral delivery of drugs in GIT requires the accomplishment of three main
aspects: (i) protection of the macromolecules from degradation; (ii) permeation through the intestinal
barrier; and (iii) absorption into the systemic circulation [10,11].
Under these requirements, oral bioavailability of sensitive molecules is recognized according
to the Biopharmaceutics Classification System (BCS) [12] as follows: (1) Class IV, drugs with low
intestinal permeability and low solubility; they have a high degree of difficulty penetrating GIT
and thus it is necessary to surpass these limitations. (2) Class III, drugs with poor intestinal
permeability and high solubility, they require an important enhancement in their permeability. In this
category, commercially relevant molecules include: insulin, glucagon-like-peptide 1 and analogues
like salmon calcitonin, octreotide, parathyroid hormone and LHRH hormone analogues such as
leuprolide. (3) Class II, drugs are concerning to macromolecules with permeability issues (high
permeability and low solubility); include molecules unfractionated such as heparin, low-molecular
weight heparins, antisense oligonucleotides and vancomycin. Finally, (4) Class I, the small molecules
with high solubility-high permeability, belong to this category; among them, bisphosphonates, acyline,
amphotericin, camptothecin and gentamycin can be found [13].
The BCS classification is considered a scientific criterion for establishing the status of oral
bioavailability of drugs; it is based on their aqueous solubility and intestinal permeability properties.
BCS leads to employ specific tests in vitro in order to predict the drugs dissolution and then to estimate
the results of their bioavailability in vivo. This procedure has a significant impact on drug policy,
making it possible to exempt bioavailability tests in vivo for class I, II and III drugs in oral solid dosage
forms, which simplifies the registration of new medicines [14]. Currently, this criterion is accepted
by different organisms, such as the U.S. Food and Drug Administration (FDA), the Brazilian Agência
Nacional de Vigilância Sanitária (ANVISA) and the European Medicines Agency (EMA) FDA, ANVISA
and EMA for biowaiver in vivo studies of sensitive molecules that have been studied under standard
solubility and dissolution values by specific in vitro trials.
Due to the importance of this topic, many researchers and different specialized companies
are found pending of the investigation and results on evolution status of the oral bioavailability
of sensitive molecules. In this regard, various studies are focused in the application of different
enhancement techniques to resolve the problems of the solubility and permeability of these
substances. The techniques are based in physical or chemical modification of the molecule, such
as: (1) Physical modification by incorporation of permeability enhancers or enzyme inhibitors, and
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use of carriers as protective and delivery systems, which can have different functions; for example,
permeability enhancer, protection against degradation, stabilizer and/or molecule carrier. (2) Chemical
modification of molecules, mainly to improve their lipophilicity, permeability and susceptibility to
degradation [5,8,10].
Many enhancement techniques comprise the application of benign biodegradable polymers,
explicitly the functionalized polymers (FP). These materials are becoming increasingly important
in specific application for oral bioavailability of drugs. FP contain polymers with specific chemical
groups, having different biological and pharmacological applications. These groups provide novel and
tailor-made properties out of existing polymers, as well as relevant advantages in drug delivery by
targeting molecules in GIT. They also improve the aqueous solubility properties of the poorly aqueous
soluble drugs, control drug release over time and improve the stability of therapeutic agents against
enzymatic degradation [15].
FP systems include different arrangements and structures, such as, FP-molecule conjugates,
molecule loaded block FP micelles and self-assembled or FP-based vehicles as microparticles
or nanoparticles.
Standard polymeric materials such as polyolefins, polyesters, polyamides, cellulose, chitosan
and nylon have been the most employed as base matrix, to obtain adequate FP in this area. The
incorporation of synthetic polymers, such as poly(caprolactone) (PCL), poly(ethylene glycol) (PEG),
poly(vinyl alcohol) (PVA), poly(acrylamide) (PAAm), poly(glycolic acid) (PGA), poly(lactic acid)
(PLA) and poly(γ-glutamic acid) (PGA), as well as their functionalization by benzaldehyde (BA),
Tetrathiafulvalene (TTF), vinil acrylic acid (VAA), boric acid (BAc) and phenolic acid (PhAc) have
attracted much attention, since they can improve the properties of these FP systems. Some of these
include biocompatibility, non-toxicity, no-allergenic properties and biodegradability. Meanwhile, the
incorporation of active groups (hydroxyl or primary amine) in these polymers have been used to attach
the molecules, achieving acceptable results like permeability enhancers, lipophilicity and protection
against the nature of enzymes or as a system for controlled drug release.
This review summarizes physical and chemical alternatives based on FP systems to enhance oral
delivery and bioavailability of sensitive molecules and their application status. The main approach of
application of FP is described for different systems as the alternative delivery in the GIT. Some of these
forms also include combined strategies of FP systems for their optimization in drug delivery.
2. Physical Modifications of FP to Enhance Oral Bioavailability of Sensitive Molecules
Currently, effective alternatives by physical modification of sensitive molecules are associated
with FP materials. FP include selective, non-toxic and biodegradable polymers with reactive groups or
responsive characteristics to enhance functional properties and oral bioavailability of these molecules.
Because of these properties, FP may enhance their stability, prolong their activity and protect them
from the harsh environments of the stomach, before releasing the drug into the more favorable regions
of the GI tract, specifically, the lower regions of the intestine. Besides, they can also maintain intimate
contact with mucus to ensure immediate absorption in the luminal fluid [5].
FP based on standard polymers such as chitosan, starch, gelatin, pectin, cellulose, carboxymethyl
cellulose (CMC), PVA and poly(lactic-co-glycolic acid) (PLGA), have been the most studied for this
purpose. Specifically, there are various properties from polymers that are exploited to modifie sensitive
molecules by FP. Particularly, some of them may act as an effective permeability enhancer, because of
their mucoadhesive or metal chelating ability. FP built by polymer combinations of PVA, PCL and PEG
present these properties and they have been used as safer strategies to increase intestinal absorption of
biomolecules [13]. Mucoadhesive FP may also increment paracellular permeability of water-soluble,
low lipophilic and poorly absorbable molecules by enlargement of tight junction (TJ) adhering to the
intracellular portion and allowing drug permeation [16].
Hydrophilic polymers like poly(vinyl pyrrolidone) (PVP) or PEG provided stability and solubility
properties to sensitive molecules, since they act as solubility enhancement. Suitable proportions of
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these polymers could give, as result, FP materials to prolong molecule shelf-life and contribute also to
stabilization against drug crystallization from the solid phase. On the contrary, other polymers such
as poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA) and polyvinyl acetate phthalate (PVAP), may be
used to modify hygroscopic materials, since carbonyl oxygens present in both polymers are used as
intermolecular H-bond acceptors [11].
Other properties like the antibacterial activity of chitosan and polycarbophil have also been
exploited to eliminate bacteria that are prone to degrade sensitive molecules [17].
From these advantages and properties that offer FP materials, their study in the application as
delivery systems of sensitive molecules has been possible. Currently, there are various forms of FP
systems to enhance their oral bioavailability: micelles, liposomes, complexes and structures with
shapes and sizes, with tailored pores, different morphologies and mechanical properties constitute
these FP systems. In addition, hydrogels, micro and nano-emulsions, nanoparticles, platelet, core–shell
structures, microspheres, pellets, dendrimers and films are some other types [18].
Figure 1 shows the most studied FP systems for sensitive molecules delivery. Several FP are
used as base materials to fulfill the purpose; such as, polysaccharides (chitosan, starch and cellulose
derivatives); proteins (gelatin, soy, casein and whey), poly(acrylic acid) (PAAc), glycerol, PEG and
various gums such as guar, xanthan, PVP and PVA [19,20].
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Figure 1. Different FP systems used to enhance the bioavailability of sensitive molecules.
Systems for drug delivery may be grouped according to Figure 2. An emulsion system can be
used for the preparation of various FP systems such as hydrogels, films, spheres and particles. In
addition, emulsion polymerization is one of the most common used methods to obtain FP materials.
Liposomes and micelles give rise to emulsions. Hydrogels and films are specific structures that are
obtained by different polymerization processes and solvent removal, whereas particles are identified
as solid forms of FP systems. In the case of dendrimers, they are structures with great advantages,
since biomolecules could be incorporated into the branches or in the periphery. In each group there are
macro-, micro- and nanosystems, where these last are currently studied as carriers in drug delivery.
Some other details of the cited systems are described below.
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delivery systems.
2.1. FP Emulsion Systems as an Enhancement Alternative of Sensitive Molecules
Systems from emulsion formulations of FP have been used as a functional method for the
entrapment or the load of sensitive molecules. They are used to encapsulate, to protect molecules and
to deliver them to very specific sites within GIT. These systems can also be used as a base to obtain FP
structures by solvent separation.
Micelles and liposomes are assembled into emulsions. Micelles are assemblies with a shell and
an inner core; they are made up of synthetic block- or graft-copolymers. Due to the hydrophobic
core, these systems could act as a reservoir for the encapsulation of hydrophobic drugs and could
cross the intestinal barrier after oral administration [21,22]. Their small size (diameter 10–100 nm)
allows a prolonged drug circulation time; they also have low toxicity and have high structural stability.
Specifically, nanomicelles are now studied for effective drug delivery to carcinogenic cells. Polymer
liposomes or vesicles are molecular assemblies of amphiphilic block copolymers or complementary
random copolymers. Because of both their hydrophobic and hydrophilic drug moieties, these systems
can encapsulate different sensitive molecules.
Chitosan, cellulose derivatives, ethylene glycol and PEG are the most used polymers in emulsions.
These systems have demonstrated ability to carry both polar and non-polar molecules, and a better
control over their release. Particularly, FP micelles nanomaterials are seen today as one promise
in the pharmaceutical area [23]. Mainly, insulin is the most studied biomolecule in FP emulsions
on diabetic rats [3]. However, some disadvantages on FP emulsions are their low drug loading
efficiency, their poor stability after administration, and their difficulty to move through paracellular
membranes; thus, several challenges need to be overcome such as their reduced loading capacity and
low physicochemical stability during long term storage [3].
2.2. FP Hydrogel and Film Systems as an Enhancement Alternative of Sensitive Molecules
FP hydrogels and films have also been considered as a possibly efficient and convenient way
to administer biomolecules. Characteristics of hydrogels and films make these systems models and
carriers for oral delivery of sensitive molecules.
Hydrogels are permanent or chemical gels stabilized by covalently cross-linked networks that
have the capacity to hold water within their porous structure. Figure 3 shows the microporous structure
of a hydrogel, which leads to the absorption and desorption of a drug.
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Due to hydrogel characteristics, these systems are considered ideal to protect the entrapped active
molecules in gastric fluid since they can protect them from degradation by digestive enzymes in the
stomach and can also inhibit the activity of Ca2+ dependent proteolytic enzymes.
Absorbent and mucoadhesive properties of hydrogels are also exploited for their use as enhancers
of sensitive molecules and delivery systems. These also enable prolonged residence time at the
absorption site. Covalent attachment of drugs offers greater control over long-term in vivo delivery.
While appropriate temporal and spatial release profiles can be designed through environmentally
responsive drug linkers.
Some FP hydrogels tested for drug delivery, are those based on chitosan and collagen,
poly(ethylene glycol) (PEG), poly(N-isopropylacrylamide) (PNIPAM) and hyaluronic acid blended
with methylcellulose (HAMC), PEG, PNIPAM and HAMC. One disadvantage of these FP systems is
their biocompatibility and adhesion of biomolecules, which can alter the polymer structure.
Concerning oral films, these are carrier systems that have mainly been studied for transbuccal
drug delivery; however, films are also considered as systems that pass through the GIT without losing
activity. In this case, part of the films can be absorbed in the oral cavity, whereas most of the drug is
absorbed after swallowing and transition to the GIT. This is possible because films may be carrier of
particles that subsequently may achieve the intestinal tract and release the drug in this place [24].
Due to their form and consistency, films may also offer the capacity to permeate trough the
intestinal epithelium, allowing the disruption of epithelial barriers, interfering with tight junctions
closing mechanism, increasing the fluidity of membranes or by decreasing mucus viscosity.
Cellulose derivatives and PVA are commonly used in films preparation. Sodium alginate,
gelatin and pectin, as well as, hypromellose with cationic copolymer based on dimethylaminoethyl
methacrylate (DMAEMA), butyl methacrylate (BMA) and methyl methacrylate (MMA) and synthetic
copolymers of macrogel-PVA, are also studied to deliver drugs in film forms.
Today, there are a few studies of these FP systems; however, these products can enhance
compliance and acceptance. Nevertheless, the small size and form of the oral films have limited
their incorporating capacities as active molecules; thus, they must be potent enough at low doses [17].
Finally, both cases, hydrogels and films, can also be designed in nanoscale, getting better the
contact area and molecule delivery. Presently these nanosystems, specifically nanofilms could offer
great possibilities of application in oral bioavailability of sensitive molecules.
2.3. FP Solid Particles Systems as Enhancement Alternative of Sensitive Molecules
Currently, FP solid particles systems are based in microparticles (MPs) and nanoparticles (NPs).
However, FP-NPs are the most studied systems in molecules delivery, because they increment their
cellular uptake through receptor-mediated endocytosis [25]. NPs are also recognized as delivery
enhancers systems that provide an added level of protection from degradation of sensitive molecules
and assist co-localized release, improving their therapeutic performance. Several studies of FP solids
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carriers have demonstrated that is also possible to enhance the molecule stability and performance.
This status is achieved by increasing drug solubility, particle wettability and particle porosity to
augment drug release. In addition, FP solid particles provide a high specific surface area for adsorption
of drug and formation of covalent attachment via amide bond formation. The FP exhibits also good
long-term dispersion stability [26].
Biodegradable polymers such as, PLGA, PEG-methyl and ether-block-polylactide (PEG-b-PLA)
are employed as base material to produce FP-NPs systems. Specifically, hydrophobic polystyrene and
chitosan are used as protective material and bioadhesive polymers.
In addition, other studies have proved that FP containing carboxylic acid groups have the ability
to protect peptides from the protease enzymes such as trypsin and chemotrypsin. These polymers
were proposed to react by the binding of divalent cations (calcium and zinc) to exhibit their enzyme
inhibitory effects [27].
Suspension, dispersion, precipitation, multistage, membrane/microchannel emulsification and
microfluidic polymerizations are the main techniques to obtain solid particles. Recent advances show
also development of FP-NPs systems from layer by layer (LBL). LBL coating of NPs are prepared as
strategy to provide a better molecule protection against gastric enzymes, as well as a delayed release,
but for prolonged period of time [28]. LBL may be composed of chitosan, alginate, poly(allylamine)
(PAA) or PAAc. Moreover, NPs may be obtained by templating mesoporous silica (MS) or with a
metallic core to obtain magnetic properties of NPs.
Disadvantages of using nanoparticles as FP systems are related with the low incorporation
efficiency of hydrophilic biomolecules, lack of precise control for drug release, tendency of particle
aggregation, and the possible accumulation of non-degradable particles in tissues [3]. However, due to
their multiples advantages as enhancement systems of sensitive molecules, these FP structures are the
most studied in drug delivery.
Currently, the NPs systems are considered as an important study area in physical modification of
sensitive molecules to cover of the requirements of cancer diseases.
2.4. FP Dendrimers Systems as Enhancement Alternative of Sensitive Molecules
Studies on sensitive molecules may also be associated with FP dendrimer to enhance their oral
bioavailability, because they have similar structures to globular proteins or sensitive molecules and
thus, are also biocompatibles.
Dendrimers are core–shell nanostructures with precise architecture and low polydispersity.
Polyvalence of dendrimer provides versatile functionalization with biological receptor sites and
functionalization of periphery can give origin at other FP systems with new properties as viscosity
and stability [29]. In Figure 4, the chief dendritic polymers used as FP systems are shown, including
dendrimer-type, linear-dendritic block copolymer, Janus dendritic polymer, dendronized polymer,
and dendritic multiarm copolymer.
The versatility of dendrimers is that, through hydrophobic interactions or through covalent
bonding, biomolecules are incorporated in the interior branches or in any place of the dendritic
structure [30].
FP dendrimer systems have been studied with the scope to analyze the solubilization of
hydrophobic small biomolecules involved in anti-cancer, -depressant, -inflammatory and -microbial
applications [31]. This method has also been widely studied for nucleic acid-based therapeutics and
other negatively charged therapeutics.
Biomolecules have been associated with FP dendrimers such as poly(amidoamine) (PAMAM),
poly(propylene imine) (PPI or DAB), and polyether hydroxylamine dendrimers (PELHAM).
FP dendrimer are considered ideal systems in sensitive molecules delivery, due to capacity for
encapsulate and compatibility with gastric fluids, however they should be designed with a better
ability to cross the intestinal barrier. Their high cost of preparation is also a disadvantage in drug
delivery area.
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Figure 4. Different architectures of dendritic polymers: (A) dendrimer-type; (B) linear-dendritic
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copolymer. Focal point of dendrimer (Red); branches of dendrimer (pink); terminal groups of
dendrimer (blue); main polymeric chain (black); another type of dendron with different functional
groups (orange).
Further opportunities of these systems as physical enhancement modification of biomolecules
is waited, because they offer different properties as viscosity, stability and various advantages of
attachment of multifunctional groups to improve the FP system.
An overview on FP mentioned systems, enhancement properties of sensitive molecules and
status of application is summarized in Tables 1–3. Emulsions, hydrogels, dendrimers, films and
solid FP systems make up this report, which is comprised since 2000 to present. FP materials and
their properties as permeability, protective enzymatic action and delivery drug control of sensitive
molecules, were considered as the highlight data to perform this summary.
Mostly, these characteristics are considered as an indicator for establishing the status of application
of molecule and safety and efficacy of a multisource finished pharmaceutical product (FPP).
As can be seen, at present, there are many FP materials integrated in different systems to
cover different demands for the bioavailability of sensitive molecules. Principally, they are built to
perform physical modifications of these molecules and then to enhance their properties of permeability,
protective action of molecule and their release control. FP materials include biopolymers like protein
and polysaccharide and synthetic or semi-synthetic polymers; mainly composites FP have been
used to prepare various formulations based in chitosan to improve molecule permeability. Thus
far, FP-emulsion and FP hydrogels have been the most promising systems to enhance this property;
nevertheless, NPs have also been the most studied systems to give response to this stimulus, with some
other advantages like protective systems, increase of the half-life of the molecule, high biocompatibility,
minimum immunogenicity, site targeting and overcoming the membrane barriers.
The most studied sensitive molecules are insulin, calcitonin and mannitol, and their results as
modified molecules by FP systems correspond primarily to in vitro studies. However, the possibility of
modifying these molecules by FP systems and their response against permeability, protective action
and optimal carrier for sensitive molecules, are useful to continue with research on this topic.
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Table 1. FP systems with permeability enhancement on sensitive molecules.
System FP Sensitive molecule References Application trials
Micelles N-trimethyl chitosan (TMC 60, TMC 40 substitution grade) Hydrophilic [14C]-mannitol [32]
In vitro, Permeability of drug by Transepithelial electrical
resistance (TEER) on Caco-2-cell
Micelles Labrasol-D-a-tocopheryl-PEG 1000 succinate (TPGS) Vancomycin hydrochloride (VCM) [33] In vitro, Permeability by plasma drug concentrationsin rat ileum
Microtablets Chitosan-4-thiobutylamidine(TBA)-BBI-chitosan elastatinal-glutathione Salmon calcitonin (cST) [34]
In vitro, Permeability by the release profile of drug.
In vivo, Plasma calcium level in rats
Microemulsion SMEDDS-Labrasol Mannitol [35] In vitro, TEER measurement on Caco-2-cell.
Film PVA-elastoid® E35H-PPR.PVP Lidocaine Hydrochloride [36] In vitro, Transdermal film in vertical Franz-type diffusion cells.
Film Pectin-chitosan Paracetamol [37] In vitro, Permeability by release of drug onfresh porcine small intestine
Emulsion Chitosan-glyceryl monostearate (GM) Enoxaparin [38] In vitro, Permeability by absorption of drug on intestinal mice
Nanoparticles Chitosan-PLA-co-glycolide)-silicon onto ofhydroxyl-propylmethyl-cellulose- acetyl-succinate Peptide Glucagon-like peptide-1 [39]
In vitro, Permeability by release of drug in
simulated fluids, SGF and SIF
Emulsion Poly(N-vinylacetamide-co-acrylic acid)-D-octaarginine, Protein (pGFP-C1), β-galactosidaseand bovine serum albumin (BSA) [40] In vitro, Permeation drugs in HeLa-cells
Nanoparticles N-trimethyl-TMC-(PLGA) Insulin [41]
In vitro, Permeability by release of drug in simulated gastric
fluid (SGF) and simulated intestinal fluid (SIF).
In vivo, Intestinal mucoadhesion in male Kumming mice.
Table 2. FP systems with protective enzymatic degradation as enhancement of sensitive molecules.
System FP Sensitive molecule References Application trials
Capsules/tablets Sodium carboxy-methyl cellulose (Na-CMC)-Bowman–Birk inhibitor conjugate Insulin [42]






Insulin and mannitol [43]
In vitro, Protective effect against intestinal
enzymes and release profile.
In vivo, Glucose levels of diabetic in mice.
Microspheres Poly(vinyl alcohol)-graft-poly(lactic-co-glycolicacid), PVA-g-PLGA
Bovine serum albumin, ovalbumin,
cytochrome c and FITC-dextran [44]
In vitro, Protective effect against intestinal
enzymes and release profile.
Nanoparticles PNC of diblock PEG-PLGA Catalase enzyme [45] In vitro, Protective effect against proteolysis.
Nanoparticles Triglyceride nanostructures-chitosan-PEG Salmon calcitonin (cST) [46]
In vitro, Protective effect by TEER measurement
on cell monolayer Caco-2.
In vivo, Serum calcium levels in rats
Nanoparticles Vitamin B12-dextran Insulin [47] In vitro, Protective effect against intestinal enzymes.In vivo, Glucose measure in diabetic rats
Block copolymer micelles Poly(ethylene oxide)–poly(propylene oxide) Efavirenz (EFV) [48] In vitro, Protective effect against intestine-mimicking.In vivo, Plasma concentration in different male Wistar rats.
Polymers 2016, 8, 214 10 of 22
Table 2. Cont.
System FP Sensitive molecule References Application trials
Nanocomplexes PAA-cetyl or cholesterylcholoroformate pendant groups Bovine Insulin [49]
In vitro, Degradation of drug by
intestinal enzymes on Caco-2 cells
Nanospheres Cationic-β cyclodextrin polymers (CPβCDs) Insulin [50] In vitro, Degradation of drug againstintestinal enzymes into SGF and SIF.
Nanocapsules Sodium caseinate and starch Fish oil powders protein [51] In vitro, Degradation of drug by intestinal enzymes.
Nanoemulsions Bovine Lactoferrin stabilized withpoloxamers (PEO-PPO-PEO) Lactoferrin [52]
In vitro, Protective degradation of
drug and antimicrobial trials.
Microcapsules PLGA Ovalbumin and tetanus toxoid (TT), [53] In vitro, Degradation of drug by intestinal enzymes.
Emulsion Chitosan-thioglycolic acid (CS-TGA) Salmon calcitonin (cST) [54]
In vitro, Protective degradation of
drug into porcine intestine mucus.
In vivo, Release of drug in male Sprague-Dawley (SD) rats
Microspheres PLGA Immuno-globulin G [55] In vitro, Preserving the integrityof the encapsulated antibody
Nano-particles Ritonavir (RTV) PEG- PVA- Pluronic
® F68, ® F127- PVP K30-
HPC and/or HPMC
Cytochrome P4503A4 (CYP3A4) and
P-glycoprotein (P-gp) [56]
In vitro, Protective degradation of drugs into cells, HepG2,
Caco-2, THP-1, A-THP-1, and CEM
Table 3. FP systems with absorption and delivery enhancement of sensitive molecules.
System FP Sensible Molecule References Application trials and results
Nanoparticles PVAL-graft-PLGA Tetanus Toxoid (TT) [57] In vitro, Release of drug into intraperitoneal mice.
Nanoparticles PLGA-mPEG Cisplatin [58] In vitro, Release of drug in SGF.In vivo, Effect of drug in female BALB/c mice.
Film Ethyl cellulose (EC)-polyvinyl pyrrolidone(PVP)-dibutyl phthalate (DBP) Propanolol Hydrochloride (PPL) [59] In vitro, Release of drug in SGF.
Nanoparticles nanocapsules Chitosan-oil nanodroplets Salmon calcitonin (cST) [60] In vitro, Release of drug in SGF.In vivo, Calcemic levels observed in rats
Nanoparticles PLA-poly(D,L-lactide-co-glycolide acid) (PLGA) Porcine Insulin [61] In vitro, Release of drug in SGF.In vivo, Glucose evaluation in diabetic rats.
Nanoparticles Polyester-polycationic polymethacrylate Tinzaparin [62] In vitro, Release of drug into intestinal rabbit.In vivo, Anticoagulant effect in rabbit
Dispersed nanoparticles in a film DOCA (HD) dispersed in polyurethane Heparin [63]
In vitro, Release of drugs into endothelial cell
(HUVEC) In vivo, Anti-proliferative effects on old
male C3H/HeN mice
Nanoparticles PLGA-NP Cyclosporine [64] In vitro, Release of drug into heparinized blood fromSD rats. In vivo, Effect of drug in male SD rats.
Vesicles PLA-b-Pluronic-b-PLA-F127-PLA Bovine insulin [65]
In vitro, Release of drug in SGF.
In vivo, Hypo-glycemic effect
in Kumming diabetic mice.
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Table 3. Cont.
System FP Sensible Molecule References Application trials and results
Nanoparticles Chitosan-triethylchitosan(TEC)-dimethyl-ethylchitosan (DMEC) Insulin [66] In vitro, Release of drug for 5 h in SGF.
Microspheres PLGA RG 503H Neurotrophic factor(GDNF) glycosylated [67] In vitro, Release of drug into cell neurite.
Tablets and pellets HPMC-CMC-EC Metoclopramide hydrochloride (MCP) [68] In vitro, Release of drug in SGF.
Microparticle Chitosan-alginate-pectin Bovine serum albumin (BSA) [69] In vitro, Release of drug in SGF.
Microspheres (DE) pectin-calcium-chitosan PCaC Mangiferin [70] In vitro, Release of drug in both SGF and SIF.
Microspheres Chitosan-glutaraldehyde Insulin [71]
In vitro, Release of drug in SGF.
In vivo, Glucose level and powerful therapeutic





[72] In vitro, Release of drugs into rat small intestine.
Hydrogel Poly(N-isopropylacrylamide-co-propylacrylicacid-co-butylacrylate) Fibroblast growth factor (bFGF) [73]
In vitro, Delivery of drug in SGF.
In vivo, Cardio-vascular function
after 28 days in old Fischer rats.
Nanoparticles Chitosan-hydroxypropyl methylcellulosephthalate (HPMCP) Insulin [74]
In vitro, Release profiles in SGF without enzymes.
In vivo, Mucoadhesion studies in male Wistar rats.
Nanoparticles Poly(lactic-co-glycolic acid) Salmon calcitonin (sCT) [75] In vitro, Release of drug into SGF and SIFIn vitro, Plasma calcium level in female SD rats.
Hydrogel Chitosan-β–glycerophosphate (β–GP) Desferroxamine (DFO) [76] In vitro, Release of drug intoendothelial cell (HUVEC).
Nanoparticles Chitosan Anticancer Gemcitabine (GC,21,21difluorodeoxycytidine) [77] In vitro, Release of drug into HT-29 cell.
Hydrogels Poly(acrylamide)-graft-κ-carrageenan(PAAm-g-CG) and sodium alginate (SA) Ketoprofen [78] In vitro, Release of drug into rat stomach.
Spherical magnetic Pectin-chitosan Diclofenac sodium (DS) [79] In vitro, Magnetically guidedtargeted drug delivery SGF.
Nanoparticles Polybenzofulvene derivative(poly-6-MOEG-9-BF3k) Leuprolide [80]
In vitro, Drug delivery on epithelial cell; 16 HBE).
In vivo, Effect of drug on male Winstar rats.
Tablets Acetylated moth bean starch (AMBS) Lamivudine [81] In vitro, Evaluation of controlled release of drug instomach of white albino rabbits.
Nanoporous peptide particles Polypeptide poly(L-glutamic acid) (PGA) Brain-derivedneurotrophic factor (BDNF) [82] In vitro, Release of drug in SGF.
Hydrogel Conjugated linoleic acid coupledwith pluronic F-127 (Plu-CLA) Docetaxel [83]
In vitro, Release of drug into
human gastric cancer cells.
In vivo, Anti-tumor effect on peritoneal gastric
cancer metastasis in male BALB/c nude mice.
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Table 3. Cont.
System FP Sensible Molecule References Application trials and results
Nanoparticles CpG-loaded onto poly(L-glutamic acid) (PGA) Oligonucleotid CpG [84] In vitro, Release of drug into peripheral bloodmononuclear cells (PBMC’s).
Microparticles Trimethyl-chitosan (TMC)-PEG-PEGDMA-MAA Interferon-β(INF-β) [85] In vitro, Drug release in SGF.In vivo, Effect of drug in rabbits.
Nanoparticle (SLN) Glyceryl monostereate-Tween 80 Efavirenz (EFV) [86] In vitro, Release of EFV in SGF.
Nanospheres Alginate-silica Indomethacin (IND) [87] In vitro, Drug delivery in SGF.
Particles PLGA-PEG Vascular endothelialgrowth factor (VEGF) [88] In vitro, Release of drug in SGF.
Hydrogel (IPN) Poly(aspartic acid); KPAspCarboxymethyl chitosan Salicylic acid [89] In vitro, Release of drug in SGF.
Film Tamarind Seed Polysaccharide (TSP)-β(1Ñ4)-D-glucan mostly Nystatin [90] In vitro, Release of drug in SGF.
Nanoparticles Poly(vinylpyrrolidone) (PVP) Ketoprofen [91] In vitro, Drug delivery into a PVP matrixof spatially confined microcontainers.
Nanoparticles Acetylated corn starch Ciprofloxacin (CFx) [92] In vitro, Release of drug in SGF.
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3. Chemical Modification on the Nature of Sensitive Molecules by FP
Oral bioavailability of drugs can be enhanced by modifying their physicochemical nature
by chemical strategies, with the scope to increase membrane permeability, penetration of
product in the GIT, protection against degradability and proteolytic stability in this place to be
absorbed transcellularly.
Chemical modifications may be performed into specific sites of the molecule or into structure
where significant advances have been found under this approach in FP applications.
Table 4 shows actual relevant structural modifications on biomolecules to enhance their
physicochemical properties.
The sequence modification of aminoacid terminal is a basic chemical strategy of FP to reduce the
enzymatic degradation of active molecules and low bioavailability after oral administration, because
of the poor absorption or susceptibility to first pass metabolism. The modification requires identifying
the vulnerable sites to perform the substitution with resistant amino acids or specific FP, because any
structural alteration may lead to reduction in biological activity.
Techniques of cyclization of sensitive molecules by FP oligopeptides as carriers of sensitive
molecules are also different strategies for their chemical modification. In this case, FP, as oligopeptides,
are attached to a drug through their amino groups, hence offering the C-terminal carboxyl group
a nucleophile to promote intramolecular activation. Conversely, if the drug is attached to the
peptide carbonyl, the N-terminal amino group will become available to eventually engage in a
cyclization-elimination for prodrug activation [93,94].
Adding protein (proteinylation) and molecules as sugars (glycation) and polyols have also been
employed for chemical modification of drugs, mainly to develop prodrugs [18]. These modifications
affect the structure and maintenance of drug, prevent the loss of the bioactivity and increment the
permeability and stability in plasma and the selectivity towards their target site. More details on this
chemical modification of drugs can be seen in [8,17].
PEGylation is also another important chemical process in drugs modification. PEGylation consists
in the conjugation of one or more PEG molecules to proteins, peptides, non-peptide molecules or
particle surface. Reactive amino acids from sensitive molecules include lysine, cysteine, histidine,
arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine, N-terminal amino group and the
C-terminal carboxylic acid. The most recent advances in biopharmaceutical polymer conjugates show
that covalent attachment of molecule with hydrophilic FP can increase the hydrodynamic radius of
molecule and thus increase its solubility [95].
In addition, PEGylation improves properties such as stability, sustained absorption, reducing
of amount of drug required for therapeutic efficacy, reduced immunogenicity and reduced
proteolysis. In general, this modification offers the possibility to tailor the requirements of different
sensitive molecules.
Currently, several modified pharmaceuticals by this via, have been approved for their application
in the treatment of different diseases and many others are in clinical evaluation; among them are
found some pharmaceutical drugs for diabetes [96]. However, these drugs have been modified for
administration by other routes, such as parental and intravaginal [97].
Chemical modification of biomolecules has also been associated with FP dendrimers systems via
chemical bonding (“prodrug approach”). Targeted delivery is possible via targeting ligands conjugated
to the dendrimer surface or via the enhanced permeability and retention effect (EPR) [98].
Polymers 2016, 8, 214 14 of 22
Table 4. Modification of the chemical nature of biomolecules with FP systems.
Enhance modification by FP Biomolecule Enhancement action References Application trials
Monomeric and dendrimeric tetrabranched
form by residue substitution Synthetic antibacterial peptide Stability to blood proteases [99]
In vitro, Antimicrobial activity
against a panel of
gram-negative bacteria
Substitution of two polycationic lipophilic-core
carbohydrate-based dendrons 2a-b and five
polycationic lipophilic-core peptide dendrons 3–6,
containing aminoacid terminal residues
Heparin (LMWH) Absorption moleculein intestinal trials [100]
In vitro, Absorption
in simulated intestine.
In vivo, Effect of drug
in LMHW rats.
PAMAM and PPI dendrimers by introducing
functional groups Methotre-xate sodium Stability of molecule [101]
In vitro, Release of molecule in
simulated gastric fluids.
The 3483 Da peptide glucagon PEGylated to amino
acid residue Lys12 (gluc-PEG-L) with branched PEG
chain of 2200 Da (gluc-PEG-B)
Glucagon Increase in adsorbing per unitsurface area rate [102]
In vitro, Release of molecule in
simulated gastric fluids.
Functionalized nanoliposomes with synthetic coupling
of the peptide (Lys-Val-Leu-Phe-Leu-Ser)
Ligand-functionalized
nanoliposomes Absorption of molecule [103]
In vitro, Release in SGF.
In vivo, Effect on neuronal
cell in rats.




L-Asparaginase (L-Asn) Stabilization of molecule [105] In vitro, Protective degradationagainst intestinal enzymes.
12 triterpenic PEGylated amine derivatives Oleanolic and maslinic acids Cytotoxicity of molecule [106]
In vitro, Apoptotic effects on
cancer-cell lines (B16single bondF10,
HT29, and Hep G2)
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Scaffolds dendrimers provide extra functional groups for drug conjugation; thus, these FP systems
are also used in chemical modifications of biomolecules. In this case, hydrophilic dendrimer conjugates
may enhance the solubility of drugs or drug-loaded devices by its inclusion into the pit of the cyclic
oligosaccharides [107]. Therapeutic molecules can also directly forms complexes with dendrimers
containing counter-charged groups [108]. This method has also been widely studied for nucleic
acid-based therapeutics and other negatively charged therapeutic.
Globally, all the reports on chemical modifications of drugs show that FP systems enhance the
ability to reduce the frequency of dosing owing to the longer circulating half-life. However, in some
cases, it has been found that dosing volumes needed for a longer duration of action can become
limiting. In addition, reactions of the immune system to modified molecules can alter it in the long
term. Consequently, many of the research based in FP are now found in development, mainly on
potential immunogenicity of the polymer.
4. Discussion
From the reviewed results about approach enhancement to oral administration of sensitive
molecules by different FP systems, significant advances in this topic and relevant data have been
identified. Since last decade, several methods have been designed and tested to find an adequate
system to deliver active molecules. Protection of sensitive molecules from degradation, prolonged
or modified release and increase of their potential activity are the main goals for the development of
these methods.
Currently, the contribution of FP systems in physicochemical modification of biomolecules is
evident. Assumptions from trials conducted on different FP systems show promising and positive
results for their formulation into effective oral sensitive molecules delivery systems.
Nowadays, some sensitive molecules are found in different research status. Some of them have
progressed to clinical tests, and thus are likely to become commercially available in the next few years.
Some are in a preclinical or discovery stage; meanwhile, others are under development.
This information is available in “Oral Proteins and Peptides Market 2015–2025” [109]. Some
relevant data of this report reveal that 76 molecules are currently in different phases of development.
Four molecules are in the late clinical test stage (phase III); from these, Oral Octreolin, Ostora and
Plecanatide are likely to be made commercially available in 2016. Diabetes stands out among the
indicated groups for which different molecules are under study. Nearly 37% of the total number of
molecules under research is being developed for diabetic disorders. Other prominent areas include
gastric disorders and bone diseases.
Despite these successful results, is necessary to increase the contribution of FP systems on oral
bioavailability of sensitive molecules, since at the moment, their contribution has been poor. More
studies in vitro and in vivo are necessary to demonstrate the enhancement in the biomolecules and to
achieve the clinical phase. In addition, no data on biowaiver of biomolecules were found that show
relative bioavailability and/or bioequivalence improvements through the FP systems or a vitro assay
on these systems that can replace in vivo studies, to ensure therapeutic equivalence and thus their
bioavailability, according BCS.
The study on FP systems as enhancement techniques for biomolecules administration has not
been easy, because each molecule requires its own specific condition for stability, solubilization and
controlled release immune elimination. Some of the most exposed problems in several reviews
are related to permeation [5,13,20,110]. The physicochemical properties of sensitive molecules and
conditions of absorption of FP systems have also limited their function [111,112]. In vitro results on the
properties of biomolecules provide relevant data to predict the in vivo performance.
Denaturation at the water/solvent interfaces is another of the major issues that lead to a decrease
in the molecule bioactivity occurring during the encapsulation process. In addition, other results have
showed that FP nano carriers can reduce the transepithelial resistance [60]; therefore, their potential
use for clinical applications is still uncertain [20]. Consequently, some FP systems still cannot be used
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in oral formats due to their low efficacy. In addition, some of them are applied and commercialized
today, and reports on clinical studies are scarce [96]. Accordingly, more studies are necessary on
the aggregation form of the molecule, as well as clinical tests. Furthermore, the biodegradability
of FP must be considered for the design of the delivery systems, due to problems associated with
long-term biocompatibility.
A restrictive assessment on toxicity of FP systems is also necessary, as well as their effects to the
intestinal epithelial cells [113]. FP may induce cell damage, mainly in buccal and intestinal cells which
may result in acute and, possibly, chronic toxic effects [114]. Impact of their toxicity can be seen in
ulcerations of the intestinal epithelium and erosions due to the ingestion of pharmaceuticals [115].
5. Conclusions
FP systems have an important contribution in the strategies for oral administration of sensitive
molecules. These systems are used in physical and chemical modification of drugs to increase their
oral bioavailability and to remain in an intact form through GIT for their release.
Nowadays, several reports have demonstrated that the efficacy of these molecules could be
improved by inclusion of FP systems and some of them are now available for consumption. However,
due to physicochemical characteristics of sensitive molecules, many challenges still exist to enable their
optimal oral supply. In addition, the higher introduction of these molecules as biopharmaceuticals
also demands a high amount of studies in this area, and requires fast results of candidates entering
clinical studies in a wide variety of therapeutic categories. Furthermore, new oral formulations based
on FP systems are necessary to enhance the bioavailability of sensitive molecules.
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